| scholarly article | Q13442814 |
| P2093 | author name string | M Takahashi | |
| T Tanaka | |||
| S Ohta | |||
| K Murata | |||
| H Otani | |||
| N Nitta | |||
| K Tsuchiya | |||
| S Kanasaki | |||
| A Seko | |||
| A Sonoda | |||
| Y Nagatani | |||
| P2860 | cites work | Cisplatin-conjugated degradable gelatin microspheres: fundamental study in vitro | Q83039562 |
| Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity | Q33366496 | ||
| A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma | Q35220471 | ||
| Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia | Q35615823 | ||
| Degradable gelatin microspheres as an embolic agent: an experimental study in a rabbit renal model | Q37062316 | ||
| Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. | Q40382328 | ||
| A phase I study of flavopiridol and docetaxel. | Q40479634 | ||
| Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms | Q40573975 | ||
| Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. | Q40715769 | ||
| Synthesis of gelatin microspheres containing interferon | Q43513049 | ||
| A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. | Q43643456 | ||
| Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol | Q44228936 | ||
| Phase II study of flavopiridol in patients with advanced colorectal cancer | Q44525933 | ||
| A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer | Q44761882 | ||
| A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. | Q46404923 | ||
| Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer | Q46487396 | ||
| A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol | Q46493704 | ||
| A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study | Q46566761 | ||
| Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. | Q46964752 | ||
| Prolonged local persistence of cisplatin-loaded gelatin microspheres and their chemoembolic anti-cancer effect in rabbits | Q47357446 | ||
| An initial clinical study on the efficacy of cisplatin-releasing gelatin microspheres for metastatic liver tumors | Q47582965 | ||
| Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits. | Q50755141 | ||
| Gelatin microspheres: initial clinical experience for the transcatheter arterial embolization. | Q50916780 | ||
| Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. | Q52184569 | ||
| Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia | Q80726129 | ||
| P433 | issue | 989 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 428-432 | |
| P577 | publication date | 2009-12-17 | |
| P1433 | published in | British Journal of Radiology | Q15758529 |
| P1476 | title | A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model | |
| P478 | volume | 83 |
| Q36325234 | Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model |
| Q35534035 | Comparison of two different laparotomy methods for modeling rabbit VX2 hepatocarcinoma |
| Q37707220 | In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening |
| Q93202753 | Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process |
Search more.